Evolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative Neoplasms

Jason B. Kaplan*, Brady L. Stein, Brandon McMahon, Francis J. Giles, Leonidas C. Platanias

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations


Despite the emergence of JAK inhibitors, there is a need for disease-modifying treatments for Philadelphia-negative myeloproliferative neoplasms (MPNs). JAK inhibitors ameliorate symptoms and address splenomegaly, but because of the heterogeneous contributors to the disease process, JAK inhibitor monotherapy incompletely addresses the burden of disease. The ever-growing understanding of MPN pathogenesis has provided the rationale for testing novel and targeted therapeutic agents, as monotherapies or in combination, in preclinical and clinical settings. A number of intriguing options have emerged, and it is hoped that further progress will lead to significant changes in the natural history of MPNs.

Original languageEnglish (US)
Pages (from-to)17-25
Number of pages9
StatePublished - Jan 1 2016


  • Combination
  • Myelofibrosis
  • Myeloproliferative neoplasm
  • Novel
  • Targeted
  • Therapy

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'Evolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative Neoplasms'. Together they form a unique fingerprint.

Cite this